Daratumumab shows great promise in published report today

The major article today in the New England Journal of Medicine is a report  of a study with lead author, Dr. Henk Lokhorst (from VU University Medical center in Amsterdam, Netherlands) which summarizes the phase I – II trials results in 72 patients treated with daratumumab, anti-CD38 therapy.